These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22792467)

  • 21. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of HMG-CoA reductase inhibitors on endothelial function.
    Tesfamariam B
    Am J Cardiovasc Drugs; 2006; 6(2):115-20. PubMed ID: 16555864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation.
    Antonopoulos AS; Margaritis M; Shirodaria C; Antoniades C
    Thromb Haemost; 2012 Nov; 108(5):840-8. PubMed ID: 22872079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
    Laufs U
    Eur J Clin Pharmacol; 2003 Mar; 58(11):719-31. PubMed ID: 12634978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome.
    Chaudhary K; Malhotra K; Sowers J; Aroor A
    Cardiorenal Med; 2013 Oct; 3(3):208-220. PubMed ID: 24454316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
    Balakumar P; Mahadevan N
    Br J Pharmacol; 2012 Jan; 165(2):373-9. PubMed ID: 21790534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation.
    Gelosa P; Cimino M; Pignieri A; Tremoli E; Guerrini U; Sironi L
    Vasc Health Risk Manag; 2007; 3(5):567-77. PubMed ID: 18078008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial cardiovascular pleiotropic effects of statins.
    Davignon J
    Circulation; 2004 Jun; 109(23 Suppl 1):III39-43. PubMed ID: 15198965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The pleiotropic effects of statins].
    Wolfovitz E
    Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of statin use on endothelial function: from bench to clinics.
    Martínez-González J; Badimon L
    Curr Pharm Des; 2007; 13(17):1771-86. PubMed ID: 17584107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Werner N; Nickenig G; Laufs U
    Basic Res Cardiol; 2002 Mar; 97(2):105-16. PubMed ID: 12002257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiorenal syndrome: long road between kidney and heart.
    Junho CVC; Trentin-Sonoda M; Panico K; Dos Santos RSN; Abrahão MV; Vernier ICS; Fürstenau CR; Carneiro-Ramos MS
    Heart Fail Rev; 2022 Nov; 27(6):2137-2153. PubMed ID: 35133552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
    Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
    Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins and inflammation in cardiovascular disease.
    Vogiatzi G; Oikonomou E; Siasos G; Tsalamandris S; Briasoulis A; Androulakis E; Latsios G; Papaioannou S; Tsioufis K; Tousoulis D
    Curr Pharm Des; 2017 Oct; ():. PubMed ID: 28990524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018.
    Verdoodt A; Honore PM; Jacobs R; De Waele E; Van Gorp V; De Regt J; Spapen HD
    J Transl Int Med; 2018 Mar; 6(1):21-25. PubMed ID: 29607300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Statins in the management of acute coronary syndrome].
    Matoba T; Egashira K
    Nihon Rinsho; 2010 Apr; 68(4):692-8. PubMed ID: 20387563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on the cardioprotective effects of statins.
    Luo JD; Chen AF
    Curr Med Chem; 2003 Aug; 10(16):1593-601. PubMed ID: 12871130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.